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High dose of dexamethasone 
protects against eAe-induced 
motor deficits but impairs learning/
memory in C57BL/6 mice
Nilton dos santos1, Leonardo s. Novaes1, Guilherme Dragunas1, Jennifer R. Rodrigues1,  
Wesley Brandão2, Rosana Camarini  1, Jean pierre schatzmann peron2 & 
Carolina Demarchi Munhoz  1
Multiple sclerosis (MS) is an autoimmune and neuroinflammatory disease characterized by 
demyelination of the Central Nervous System. Immune cells activation and release of pro-inflammatory 
cytokines play a crucial role in the disease modulation, decisively contributing to the neurodegeneration 
observed in MS and the experimental autoimmune encephalomyelitis (EAE), the widely used MS animal 
model. Synthetic glucocorticoids, commonly used to treat the MS attacks, have controversial effects 
on neuroinflammation and cognition. We sought to verify the influence of dexamethasone (DEX) on 
the EAE progression and on EAE-induced cognitive deficits. In myelin oligodendrocyte glycoprotein 
peptide (MOG35-55)-induced EAE female mice, treated once with DEX (50 mg/kg) or not, on the day 
of immunization, DEX decreased EAE-induced motor clinical scores, infiltrating cells in the spinal cord 
and delayed serum corticosterone peak. At the asymptomatic phase (8-day post-immunization), DEX 
did not protected from the EAE-induced memory consolidation deficits, which were accompanied by 
increased glucocorticoid receptor (GR) activity and decreased EGR-1 expression in the hippocampus. 
Blunting hippocampal GR genomic activation with DnGR vectors prevented DEX effects on EAE-induced 
memory impairment. These data suggest that, although DEX improves clinical signs, it decreases 
cognitive and memory capacity by diminishing neuronal activity and potentiating some aspects of 
neuroinflammation in EAE.
Human and animal studies have revealed a clear relationship between glucocorticoids (GCs) and some 
brain-related disorders, such as anxiety, depression, dementia, and schizophrenia1,2. Several brain regions, such 
as the medial prefrontal cortex (mPFC), hippocampus, and amygdala orchestrate cognitive functions in health 
and disease. In this context, morphological and activity modifications induced by endogenous or synthetic GC 
administration in these brain areas can change the hypothalamic-pituitary-adrenal (HPA) axis activity, causing 
anxiety, memory impairment and other brain disorders3,4.
High doses of synthetic GC, such as dexamethasone (DEX), prednisolone, and methylprednisolone, are 
commonly used to suppress immune activation and to treat the onset of the acute inflammatory symptomatic 
phase in relapse-remitting multiple sclerosis (MS-RRMS) patients, which becomes less effective across the MS 
clinical progression. GC can, indeed, alleviate the evolution of EAE in a dose-dependent manner5. However, 
GC (e.g., dexamethasone), whose metabolism in the organism ranges from 34 to 56 hours, can lead to wors-
ening effects in the memory and locomotor activity6. In addition, several studies using different approaches 
showed the pro-inflammatory GC effects in the central nervous system (CNS), with increased NFKB activation, 
pro-inflammatory cytokines (IL1β, TNF-α) levels and reactive oxygen species (ROS) production, and inhibited 
neurogenesis in hippocampus and frontal cortex, both in vivo and in vitro7–9.
The EAE, an experimental model of MS, exhibits very similar histopathological and biomolecular mark-
ers10,11. Innate and acquired immune responses are implicated in both MS and EAE pathogenesis, including major 
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histocompatibility complex (MHC) presentation of myelin-derived epitopes and cytokines release by dendritic 
cells and macrophages, activation of T lymphocytes (CD4+ and CD8+ T cells) into the perivascular region of the 
brain and spinal cord white matter, increased glial activation, and neurodegeneration12,13. Altogether, this implies 
in severe motor, sensory, autonomic, and neurocognitive clinical symptoms13,14.
Along with physical impairments, MS is also associated with behavioral, neuropsychiatric, and cogni-
tive deterioration15. Indeed, 50% of MS patients are depressed16 and show cognitive deficits17; anxiety affects 
more than 35%, and chronic fatigue affects 50–60% of MS patients18. Recent experimental studies have shown 
that Biozzi ABH mice immunized with myelin oligodendrocyte glycoprotein (MOG35-55), which exhibits a 
remitting-relapsing EAE, presented hippocampal LTP (long-term potentiation) dysfunction, affecting aversive 
and non-aversive memory consolidation19. These effects on LTP and spatial memory impairment appeared to be 
dependent on IL-1β release and the oxidative stress induced by NADPH oxidase overexpression. In these settings, 
methylprednisolone treatment did not prevent the excitatory postsynaptic currents (EPSC) deficits in the hip-
pocampus of immunized animals19. Also, EAE animals in the pre-symptomatic phases showed memory deficits in 
water maze tasks, which were dependent of TNF-α and IL1β mRNA overexpression in the hypothalamus but not 
in the amygdala or hippocampus of EAE mice20. These cytokines have a significant role in sterile inflammation 
and autoimmune diseases, contributing to the inflammatory cascade within CNS after EAE onset21.
In this sense, the MS and EAE-induced dysregulation of the HPA axis and neuroinflammation can be related 
to mood and cognitive symptoms14,22. Also, the treatment with synthetic GC could produce GR resistance 
through different mechanisms, such as (1) alternative splicing generating GRβ isoform in humans, (2) transacti-
vation of others transcription factors, i.e., AP-1, and (3) modulation by non-classic kinases pathways, i.e., MAP 
kinases23. Furthermore, the augment of GC release by different types of stress can either protect24 or potentialize25 
EAE progression.
This study aimed to elucidate the role of GCs signaling in the hippocampus after EAE- and DEX-induced cog-
nitive impairment, focusing on the canonical GR signaling in CNS via recruitment of the CREB-EGR-1 pathway 
involved in neuronal activity and plasticity. Our results showed that although the treatment with DEX on the day 
of EAE induction has protected against motor signals progression, it induced HPA axis malfunction and dimin-
ished neuronal activity in the dorsal hippocampus, which was associated with memory loss related to EAE. These 
DEX effects were accompanied by a decreased CREB activity and EGR-1 expression during the disease.
Results
Dexamethasone protects against EAE clinical signs and delays the peak of serum corticosterone. 
Schematic timeline for the experimental design of EAE is exposed in Fig. 1A. We observed the appearance of the 
clinical signs in the mice immunized with MOG35-55 in CFA (Complete Freund Adjuvant) at the 10-day post-im-
munization (dpi; Fig. 1B). The clinical scores peaked at the 16 dpi and partially remitted at the 26 dpi when the 
clinical scores from EAE mice were different from those in the EAE + DEX group (F = (24,742) = 5,113; interac-
tion, p = 0,0001) (Fig. 1B).
DEX (50 mg/kg) treatment alone had no effect on the appearance of clinical signs. Despite both EAE and 
EAE + DEX groups began to present the motor deficits at the same day (10th dpi), the EAE + DEX group 
exhibited lower scores than EAE from the 13 dpi until the 26 dpi, showing that DEX attenuated the EAE motor 
signs development (F = (17,170) = 2,508; interaction, p = 0,0014) (Fig. 1B). Moreover, the sum of the scores in 
EAE + DEX animals was also lower than EAE during the disease (p = 0,0481) (Fig. 1C). In addition to the atten-
uating effect on the clinical scores in EAE mice, this drug diminished the inflammatory cells infiltration in the 
spinal cord of diseased animals at the remission phase (p = 0,0397) (26 dpi, Fig. 1D,E).
Several studies have shown HPA axis dysregulation in EAE and multiple sclerosis. Here, we observed that 
DEX indeed blunted corticosterone release up to 48 hours after its administration (F (1,43) = 75,29; DEX effect, 
p < 0,0001) (Fig. 2A), showing its suppressive effect on the HPA axis. No differences were found on the CORT 
serum levels at the 8 dpi (Fig. 2B) when all behavioral and biochemical analysis were made. As suggested in 
several studies, in EAE mice, we observed that serum corticosterone levels followed the magnitude of clini-
cal scores, peaking at the 16 dpi (interaction, F(1,14) = 8,662; P = 0,0107) (Fig. 2C), reducing pursuant to the 
decreased severity of the motor deficits scores and returning to control levels at the 26 dpi (Fig. 2D). However, in 
DEX-treated EAE-induced mice, serum CORT peak was prevented at the 16 dpi (Fig. 2C), shifting to the 26 dpi 
[Dex effect, (F(1,15) = 21,57; P = 0,0003)] (Fig. 2D). These results suggest that DEX treatment changes the HPA 
axis activity throughout the disease.
DEX did not protect against memory acquisition/consolidation deficits in EAE. In addition to 
the motor signs, both EAE-induced animals and MS patients show mood and memory disorders. Here, we tested 
whether DEX treatment would impact the working memory acquisition/consolidation in EAE-induced animals 
at the asymptomatic phase (7 and 8 dpi, before the onset of the clinical signs).
Using the Novel Object Recognition test (NOR), we addressed DEX modulation of learning and memory in 
EAE mice. In our experimental conditions, at the 8 dpi, both EAE and EAE + DEX groups showed decreased 
working memory consolidation in the EAE group, measured 2 and 24 hours after training, (DEX factor, F 
(3,55) = 21,51; P < 0,0001, Fig. 3A,B).
To confirm that DEX specifically caused the cognitive impairment, another set of animals receveid fingolimod 
(FTY-720), a sphingosin1-phosphate receptor modulator, 10 mg/kg, the first FDA-approved oral treatment for 
MS, on the day of immunization. In contrast to DEX treatment, fingolimod protected against memory loss in 
NOR in the same settings that DEX worsened it, 2 and 24 hours after training (interaction, F = (1,13) = 29,66; 
P = 0,0001), and also reduced the clinical scores in EAE-treated mice (data not showed) (Fig. 3C,D). In our set-
tings, EAE did not impair the contextual fear memory, suggesting that the acquisition of aversive memories is not 
affected after 8 dpi (Fig. 4).
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DEX decreased neuronal activity via GR signaling in the dorsal hippocampus of EAE mice in the 
absence of motor signs (8 dpi). EAE cognitive effects can be associated with pro-inflammatory tran-
scription factors activation in the hippocampus. Initially, we investigated the GR activity, using its nuclear 
Figure 1. Evaluation of the clinical score over time of C57BL/6 female mice immunized with MOG35-55 emulsified 
with CFA, treated with Dexamethasone (DEX, 50 mg/kg) or Fingolimod (FTY-720, 10 mg/kg) at the day of 
immunization. (A) The schematic timeline for the experimental design. (B) Treatment with DEX on the day of 
immunization protected against EAE clinical score evolution; dotted arrows indicate the day of the euthanasia. (C) 
The sum of the total score from each animal at the 26 dpi was used to determine disease severity. (D) Hematoxylin-
Eosin staining of mice spinal cord, arrows showed infiltrating clusters of peripheral cells in EAE and EAE + DEX. 
(E) Density of infiltrating cells in the white matter of EAE and EAE + DEX spinal cords/100 μm2. The results are 
showed as mean ± SEM of the experimental groups (N = 18). *p < 0.05 vs EAE [Two-way ANOVA followed by 
Bonferroni post-test (B), bi-caudal T-test (C) and Mann-Whitney non-parametric test (E)].
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translocation as an index of activation. EAE animals, even in the absence of clinical signs, showed increased 
GR translocation in the dorsal hippocampus when compared to control groups, an effect that is not modulated 
by DEX treatment (EAE factor: F (1, 12) = 25,17; P = 0,0003) (Fig. 5A). No differences were found in total GR 
expression (total protein extract) in the hippocampus among the groups (Fig. 5B).
Considering that the decrease in learning/memory acquisition could be related to disrupted hippocampal 
functions, we investigated the activity of the protein kinase ERK1/2, the transcription factor CREB, and the 
immediate early gene EGR-1, the latter as an indicator of neuronal activity. There was no difference in the ERK1/2 
activity in the dorsal hippocampus among groups, measured by the ratio between the phosphorylated (Ser 133) 
and total ERK isoform expressions (Fig. 5E). However, DEX treatment, irrespective of the disease, decreased 
CREB phosphorylation in the serine 211 residue at the 8 dpi (DEX factor (1, 11) = 6,241 P = 0,0296) (Fig. 5C).
CREB phosphorylation on Ser 211 residue can increase its binding to DNA and promotes the transcription of 
immediate early genes, such as EGR-1. Here, DEX treatment diminished the expression of EGR1, measured after 
NOR test, in both western blot analysis (F (1, 12) = 6,378; P = 0,0266) (Fig. 5D) and immunohistochemistry (F (1, 
9) = 17,50; P = 0,0024) (Fig. 6A,B) of CA1 of dorsal hippocampus only in those animals with EAE, in agreement 
with the behavioral data obtained at the 8 dpi.
Overexpression of dominant negative form of GR protected against learning/memory disrup-
tion in EAE animals at 8 dpi. To verify the role of GR in DEX-induced cognitive deficits in EAE mice, we 
overexpressed the DnGR transgene in the hippocampus of EAE-induced mice. The overexpression of the DnGR 
prevented the effects of DEX-induced cognitive impairment in EAE animals, confirming that GR can impair 
the learning and consolidation of working memory at 2 (P = 0,0087) and 24 hours (P = 0,0152) after training 
(Fig. 7B–D). In addition, and corroborating our hypotheses, EAE + DEX-P1005 group showed reduced EGR1 
expression in the hippocampus compared to EAE + DEX-DnGR animals (Fig. 7E).
Figure 2. Dexamethasone treatment delays the peak of serum corticosterone levels in EAE animals. (A) 
Corticosterone time curve after DEX treatment: 30 min, 4 h, 6 h, 24 h, and 48 h. (B) There were no differences in 
serum corticosterone levels among all groups at the 8 dpi. (C) EAE increased serum corticosterone levels at the 
peak of disease (16 dpi), an effect prevented by DEX treatment. (D) EAE + DEX animals showed high levels of 
serum corticosterone when compared to the control group at the 26 dpi. The results are shown as mean ± SEM 
of the experimental groups. *p < 0.05 vs control, #p < 0.05 vs DEX, and $p < 0.05 vs EAE. Two-way ANOVA test 
followed by Bonferroni post-test, n = 4 to 6 for each group.
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Discussion
Neuroinflammation is critically involved in several disorders of CNS and understanding its mechanisms may 
evidence essential targets for the development of new therapies. MS and EAE usually present numerous pro 
and anti-inflammatory markers, which modulate the disease evolution26,27. Glucocorticoids are well known 
Figure 3. Fingolimod but not dexamethasone protects against memory loss after EAE induction at the 8 dpi, 
on Recognition Novel Object Task. (A) No differences in discrimination ratio were found among groups at the 8 
dpi, the training day. (B) EAE and EAE + DEX groups showed decreased memory consolidation 2 and 24 hours 
after training. (C) No differences were founded in discrimination ratio in all groups after Fingolimod (FTY-720) 
treatment, 8 dpi. (D) Treatment with FTY-720 protects against working memory impairment promoted by EAE 
2 and 24 hour after training at 8 dpi. Results are shown as mean + SEM of the experimental groups. *p < 0.05 vs 
control; #p < 0.05 vs DEX or FTY-720. Two-way ANOVA test followed by the post-test Bonferroni, n = 6 to 12 
for each group.
Figure 4. EAE did not change aversive memory acquisition in fear conditioning to context. Mice were trained 
at 7 dpi in a particular context. Next day (8 dpi), mice were placed in the same context, and their freezing 
responses were measured for the 5 minutes. Differences in freezing were found among control and DEX groups 
at the 8 dpi. The results are expressed as the mean ± SEM of the mean of the experimental groups. *p < 0.05 vs 
control. Two-way ANOVA test followed by the post-test Bonferroni, n = 5 and 7 for each group.
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Figure 5. Dexamethasone treatment increases cytoplasmatic GR and decreases EGR-1 expression, at the 8 
dpi, in the EAE dorsal hippocampus of C57BL/6 female mice immunized with MOG35-55 plus CFA, treated 
(DEX + EAE) or not (EAE) with dexamethasone (DEX, 50 mg/Kg) on the day of immunization. Western Blot 
analysis of proteins in the cytosolic and nuclear fractions. Upper panel: Representative image of the Western 
blot assay. Bottom panel: densitometric analyzes of the specific bands represented in the upper panel. (A) 
Glucocorticoid receptor (GR) translocation expressed by the nuclear and cytosolic GR expression ratio. (B) 
Total expression of GR. (C) CREB activation expressed by the ration of the phosphorylated (pCREB) and total 
(CREB) forms of the transcription factor CREB in nuclear extracts. (D) Nuclear EGR-1 protein expression in 
nuclear extract. (E) ERK activation expressed by the ration of phosphorylated (pERK) and total (ERK) ERK 
cytosolic expression. The results are expressed as the mean ± SEM of the mean of the experimental groups. 
*p < 0.05 vs control; #p < 0.05 vs DEX; and $p < 0.05 vs EAE. Two-way ANOVA followed by Bonferroni post-
test, n = 4 for each group.
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immunosuppressive drugs world-widely used in allergic diseases, organ transplantation, and autoimmune dis-
eases such as MS28. The effectiveness of GC treatment in alleviating EAE-induced motor scores and peripheral 
inflammation is also showed in several settings5,24. In our paradigm, animals with EAE treated with dexa-
methasone (50 mg/kg) showed significant improvement of the clinical motor signs throughout the disease and 
decreased immune cells infiltrate in the spinal cord, evidencing the systemic immunosuppressive effect of GCs.
Although dexamethasone treatment has been protective against EAE motor signs progression in our study 
as in others, the role of GCs in neuroinflammation and cognition during EAE is quite controversial. Wurst and 
colleagues (2012) showed that methylprednisolone modulates the clinical signs after EAE immunization in a 
dose-dependent manner, with lower doses (20 mg/kg) being protective and higher doses (100 mg/kg, closest to 
the ones used in MS attacks) potentiating the motor deficits in ill animals5. These findings suggest that higher 
doses of methylprednisolone do not improve the treatment efficacy and may induce GC resistance by an HPA-axis 
dysregulation5 and the facilitation of alternative splicing of GR, generating two highly homologous isoforms: GRα 
and GRβ, this last one transcriptionally ineffective in humans29.
Unlike endogenous GCs, synthetic ones, such as dexamethasone, cannot be inactivated by the corticosteroid 
11-beta-dehydrogenase isozyme 2 (11β-HSD2) and do not bind the corticosteroid-binding globulins, resulting, 
therefore, in an increased half-life. In addition, synthetic GCs such as dexamethasone crosses the blood-brain 
barrier, acting directly on neural cells30. In this context, synthetic GCs can exert their effects and promote HPA 
axis dysregulation with adverse effects such as the accumulation of fat in the extremities, rashes, hypertension, 
muscle atrophy, and neurological effects such as depression, anxiety and memory impairment31. A recent study 
from our group revealed that rats exposed to two-hour restraint stress exhibited anxiety-like behavior 10 days 
after stress, with no difference in serum corticosterone levels, evidencing that glucocorticoids induce long-lasting 
plasticity in the brain and modifies the behavior32. Also, Mitra and Sapolsky 2008, showed that a single adminis-
tration of corticosterone increased anxiety and dendritic hypertrophy in the basolateral amygdala of rats 12 days 
after CORT administration but not before33. Moreover, stress and glucocorticoids changes spine and synapse 
density in the prefrontal cortex and hippocampus, as well. In the hippocampus, acute stress deeply affects gluta-
matergic transmission34.
GCs’ pro-inflammatory effects in the brain are well established and are dose-dependent. Higher con-
centrations administration, similar to the doses used to treat chronic inflammatory diseases (e.g., arthritis), 
Figure 6. Dexamethasone did not protect against EGR-1 reduced expression, at the 8 dpi, in the EAE dorsal 
hippocampus of C57BL/6 female mice immunized with MOG35-55 plus CFA, treated (DEX + EAE) or not (EAE) 
with dexamethasone (DEX, 50 mg/Kg) on the day of immunization. (A) Representative photomicrographs (4x 
and 20x) of the immunohistochemistry assay. (B) Densitometric analyzes of the CA1 positive cells represented 
in the upper panel. Results are shown as mean ± SEM. *p < 0.05 vs control. Two-way ANOVA followed by 
Bonferroni post-test, n = 3 to 4 for each group.
8Scientific RepoRts |          (2019) 9:6673  | https://doi.org/10.1038/s41598-019-43217-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
stroke-induced edema or immune-related diseases (e.g., MS) increases, in several experimental settings, the lev-
els of pro-inflammatory cytokines, as well as the NFKB activation in the hippocampus and frontal cortex of rats 
(for review see35). Furthermore, GR from both neurons and glia may contribute to pro- or anti-inflammatory 
Figure 7. DnGR hippocampal CA1 administration reversed memory impairment in EAE + DEX animals at the 
8 d.p.i. (A) GFP positive neurons in CA1 infected with DnGR. (B) Both p1005 and DnGR mice did not show 
differences in the discrimination ratio in the training day, at the 7 d.p.i. (C) Hippocampal DnGR overexpression 
protected against the EAE- induced decrease in memory consolidation 2 and (D) 24 hour after training in NOR 
test. EGR1 expression in dorsal hippocampus of EAE + DEX transfected with DnGR. Full arrows represent 
HSV-GFP transfection in fibers of hippocampus. Dashed arrows represent EGR-1 positive cell in CA1 of 
hippocampus. Representative photomicrographs (4x and 20x) of the immunofluorescence assay. Results are 
shown as mean + SEM. *p < 0.05 vs EAE + DEX/p1005 group. Mann-Whitney non-parametric test, n = 6 for 
each group.
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effects of GC in subventricular brain regions. Hippocampal CA1 area, for example, presents high levels of GR30 
and excitatory neurotransmitters (e.g., glutamate), being a brain structure highly susceptible to GC’s effects and 
excitotoxicity, respectively.
In our EAE paradigm, DEX modulated the HPA axis throughout the disease. First, corticosterone release was 
suppressed for at least 48 hours after DEX administration and returned to control levels after 8 days. Also, DEX 
treatment delayed CORT serum peak in EAE-induced mice. This late HPA activation differentially modulated GR 
and MR functions in the hippocampus, one of the brain regions implicated in memory processes30,36. In our study, 
DEX increased GR activity before the appearance of clinical signs, without changing MR signaling (data not shown).
Cognitive impairment and mood disorders are present in MS and EAE14,37 and glucocorticoids are well known 
to modulate cognition38,39. Nonetheless, this is the first study showing that DEX treatment, the gold standard 
for MS attacks control, did not protect against memory loss in EAE-induced mice and induced working mem-
ory deficits in EAE mice. Also, DEX treatment decreased acquisition in both working and aversive memories, 
evidencing the role of HPA axis in cognition. The effects of GCs on memory is also controversial, and several 
studies showed that the dose-dependent administration of glucocorticoids increased memory consolidation after 
training. However, high doses of GC without noradrenergic activation can impair the memory acquisition and 
consolidation40.
This effect was DEX-specific since fingolimod treatment (FTY-720), in the same settings that DEX, improved 
memory consolidation in EAE-animals in the asymptomatic phase. Fingolimod is a modulator of sphingosine 
1-phosphate receptor, capable to promotes this receptor internalization and degradation41. Also, it is the first 
FDA-approved oral treatment for MS. In the peripheral system, this immunomodulator inhibits cell prolifer-
ation and infiltration in the CNS by decreasing STAT3 signaling and consequent inhibition of TH17 lympho-
cytes42. Several studies showed that FTY-720 promotes BDNF release43 and the elevation of neural stem cells in 
the hippocampus of mice via MEK/ERK signaling44. In contrast, early-life DEX and CORT exposition reduces 
CREB-BNDF-TrkB signaling in the hippocampus and promotes cognitive impairment in rats45,46. Differences 
between GCs and FTY-720 in non-aversive memory consolidation can be associated with the activation of differ-
ent intracellular pathways in neurons47 and glial cells19,20.
In EAE models, neuronal death can be increased by retrograde neurodegeneration, decreased neurogenesis, 
and neuroinflammation. Di Fillippo and colleagues (2016) showed that IL1-β could disrupt EPSC amplitude in 
EAE hippocampal slices mediated by microglia and Acharjje et al., (2013) found that EAE impairs different types 
of memory in animals before the onset of clinical signs via microglial activation and pro-inflammatory cytokine 
mRNA in the hypothalamus. Altogether, these data corroborate our findings, where EAE-induced animals treated 
with dexamethasone showed working memory impairment and reduced neuronal activity measured by EGR-1 
expression and CREB activity in the hippocampus.
CREB can be activated by phosphorylation via the MAP kinase pathway, resulting in its nuclear translocation 
and transcription activity of proliferative and immediate early genes such as bdnf, egr-1 and c-fos48. Several studies 
showed correlations between EGR-1 expression and LTP maintenance in the hippocampus, with repercussion in 
learning of different tasks49,50. Furthermore, male mice exposed to chronic unpredictable stress showed reduced 
levels of Egr1 mRNA in the hippocampus associated with cognitive impairments in the Morris water maze, novel 
object recognition and location tasks associated to CA1 dendrites atrophy51.
In this study, we found that DEX decreased the memory acquisition in non-aversive test (NOR), a phe-
nomenon dependent on hippocampal activity. Whereas, there is no significant decrease in the acquisition of 
aversive contextual memory in the EAE groups. In accord, Acharjee and collegues 2013 suggests that release of 
cytokines in EAE impairs memory extinction but not acquisition20. In our study, EAE + DEX group also pre-
sented reduced levels of EGR-1 protein expression in the dorsal hippocampus, suggesting that the GR genomic 
action can decrease neuronal activity in the CA1 after 8 dpi, in an inflammatory environment. Also, overex-
pression of the dominant negative form of GR in the hippocampus reversed the learning and memory defi-
cits in DEX-treated EAE animals at the asymptomatic phase, confirming that GR transcriptional activity in an 
inflammatory environment is essential for the cognitive impairment in EAE. It is, therefore, imperative to know 
whether this modulation depends on the other areas of the limbic system and glial cells, which have a crucial role 
in neuroinflammation and synaptic plasticity52,53.
In summary, dexamethasone showed distinct actions in periphery and CNS, decreasing immune activation 
and protecting against clinical sings progression of EAE, as well as increased inflammation in CNS via GR sig-
naling, inducing memory/learning impairment and decreasing hippocampal neuronal activity in EAE mice. 
Altogether, our data suggest that glucocorticoid treatment, although has beneficial effects on the suppression 
of the immune system, thus, reducing the acute peripheral immune activation and further CNS infiltration, it 
seems to be crucial to the induction of cognitive impairment in some auto-immune, inflammatory conditions. 
Moreover, strengthening the current literature about the pro-inflammatory GC effects, in our EAE paradigm, GR 
signaling contributed not only to the maintenance of inflammation but also decreased neuronal activity caused by 
EAE in the mice CA1 hippocampi. Further studies are needed to elucidate whether and which post-translational 
and non-canonical mechanisms are involved in the pro-inflammatory GCs actions. Also, it is necessary to inves-
tigate the involvement of glial cells in this context, since these cells express GR, are widely known as modulators 
of neuronal activity, and have a crucial role in the inflammation of the CNS.
Materials and Methods
Chemicals and kits. Bradford Protein Assay Kit was obtained from BioRad (Hercules, CA, USA). 
Corticosterone EIA Kit was obtained from Enzo Life Sciences Inc (Farmingdale, NY, USA). MOG35-55 was 
obtained from Proteimax Technology (São Paulo, SP, BR). Mycobacterium tuberculosis and dexamethasone 
21-phosphate disodium salt were obtained from Sigma Aldrich, St. Louis, MO, USA. Unless otherwise stated, the 
chemicals were from Sigma Aldrich.
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eAe induction. All experimental procedures, including immunization, infusion, and decapitation of ani-
mals, were approved and performed according to the standards of the Ethics Committee for Animal Use of the 
Institute of Biomedical Sciences/University of São Paulo (CEUA/ICB-USP). The procedures are by the guidelines 
of the Brazilian National Council for the Control of Animal Experimentation (CONCEA), under the Brazilian 
National Law number 11794 from 10/08/2008, which regulates all research activities involving animal use in the 
country. All efforts were made to minimize the number of animals used and their suffering.
EAE was induced as previously described by Inoue et al.54, with some modifications. On the day of immuni-
zation (day 0), C57BL/6 female mice were subcutaneously injected with 150 μg of MOG35-55 peptide emulsified 
in CFA (v/v) with 400 μg of heat-killed Mycobacterium tuberculosis. Also, 200 ng of Bordetella pertussis toxin 
was administered intraperitoneally (I.P.) twice, at 0- and 48-hours post-immunization. The acute high dose of 
Dexamethasone - DEX (50 mg/kg)23 or Fingolimod - FTY (10 mg/kg) was administrated (I.P.) on the immuniza-
tion day. The animals were evaluated daily based on clinical scores (described below) to address the clinical signs 
of EAE and underwent euthanasia either by decapitation or transcardially perfusion under isoflurane anesthesia 
on the 8-day post immunization (dpi), corresponding to the pre-clinical phase of the disease. Control, no-EAE 
animals were inoculated with PBS emulsified in CFA.
Animals were evaluated daily, and the degree of clinical signs was distributed as follows: (0) without disease; 
(0.5) loss of tail tonus; (1) hind limb weakness; (2) One hind limb paralyzed; (3) Complete hind limbs paralysis; 
(4) Hind limbs paralyzed, weakness in forelimbs and (5) tetraplegia or death.
Novel Object Recognition Test (NOR). The NOR test analyzes the capacity of the animal to recognize a 
novel object based on the rodent’s natural tendency to explore new objects in their environment. Here, we used a 
protocol based on Leger at al, 2013 with few modifications55. Initially, in the habituation phase, each animal could 
explore the open field arena for 3 consecutive days from the 4 dpi to the 6 dpi. On the 7 dpi, in the training phase, 
each mouse was placed in the open field arena, which contained two identical objects (A and B), and allowed free 
exploration, for 10 minutes. Two (7 dpi) and 24 hours (8 dpi) after training, the object B was replaced by another 
(C and D, for short-term memory [STM] and for long-term memory [LTM], respectively) and the animals were 
returned to the open field arena for another 5 minutes to test the STM and LTM. Exploration was considered 
when the animals sniffed or touched the object with their nose or forepaws. A dim light illuminated the arena 
homogeneously. All trials were videotaped and, to avoid olfactory clues, the maze was cleaned with 5% (vol/vol) 
ethanol after each trial. Discrimination ratio in the training session was expressed by the ratio of the time explor-
ing the right object and time exploring the left object (TR/TL). Discrimination index after the test sessions was 
expressed by the ratio (TN)/(TN + TF) [TN = time exploring the novel object, TF = time exploring the familiar 
object]. The experiments were conducted at the 7 dpi, characterized by the high peripheral inflammation without 
motor symptoms.
Contextual fear conditioning. A fear conditioning experiment was carried out for two days in 
22 cm × 22 cm × 20 cm boxes. On day 1, a mouse was placed in a conditioning chamber for 2 min, where, after 
this, it received an electric shock (0,5 mA, 1 s). On day 2, the mouse returned to the same box for 10 min. Freezing 
was defined as the lack of all movement of the body and vibrissae. A video camera recorded each experiment and 
the freezing time was analyzed during the first 5 min. The box was cleaned with 5% ethanol between each trial. 
Each video was renamed and analyzed blinded by two different evaluators.
serum corticosterone concentration. Serum corticosterone (CORT) was measured by Corticosterone 
EIA kit (Enzo Life Sciences, Inc), according to the manufacturer’s instructions. Serum was obtained from trunk 
blood. After collection, trunk blood samples could clot at room temperature for 30 min. The blood was then cen-
trifuged at 4,000 rpm for 10 min, and the serum was transferred to a clear tube and stored at −80 °C until CORT 
analysis was conducted. Serum samples were diluted 1:30 and processed following manufacturer’s instructions.
Immunohistochemistry for EGR-1. EGR-1 immunohistochemistry was used to assess neuronal activa-
tion in the CA1 and the dentate gyrus (DG) of the hippocampus of control, DEX, EAE, and DEX-treated EAE 
groups. Animals were transcardially perfused with ice-cold saline 0.9%, followed by ice-cold 4% paraformal-
dehyde in 0.1 M phosphate buffer pH 7.4. The fixed brains were removed from the skull and cryoprotected in a 
solution of 30% sucrose in 0.1 M phosphate buffer pH 7.4 at 4 °C. They were then frozen on dry ice and sectioned 
in the coronal plane at 40 μm thickness in a Leica semi-automatic cryostat (model 1850 UV, Leica Microsystems, 
Wetzlar, Germany).
Free-floating sections were blocked with blocking serum (3% donkey serum + 0,3% Triton X-100 in PBS) 
for 2 hours at room temperature. Subsequently, the sections were incubated with primary antibody Anti-EGR-1, 
1:2000 (Santa Cruz Biotechnology, Dallas, TX, USA) diluted in blocking serum, overnight at 4 °C. After incuba-
tion with the primary antibody, the sections were incubated with the secondary antibody (goat anti-rabbit IgG, 
Vector, Burlingame, CA; dilution 1:2000) diluted in PBS + 0,3% Triton X-100 for 2 hours at room temperature, 
protected from light. The antigen-antibody complex was visualized using the avidin-biotin complex (Elite kit; 
Vector: dilution 1:200), and 3,3′-diaminobenzidine (DAB) was used as a chromogen. The peroxidase reaction 
product was developed using the glucose oxidase procedure56. The brain sections were mounted on gelatin-coated 
microscope slides, air-dried, dehydrated through an ascending series of alcohols, cleared with xylene, and cover-
slipped with DPX mounting medium.
Positive cells were observed with a Nikon Eclipse 80i microscope (Nikon Instruments Inc., NY, USA). The 
images were captured through the Nikon Digital Camera DXM 1200 C and analyzed by NIS-Elements Advanced 
Research 2.30 Image Software (Nikon Instruments Inc.). Eight boxes of 100 µm2 were used to measure the 
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integrity density in the granular layer of CA1 of the dorsal hippocampus. The mean of four sections of each ani-
mal was used to determine differences between experimental groups.
Tissue samples preparation. Nuclear and cytosolic protein extracts were prepared using the CelLytic™ 
NuCLEAR™ Extraction Kit (Sigma-Aldrich Co.), as briefly described below. Dorsal hippocampi were homoge-
nized in cold lysis buffer (10 mm HEPES, pH 7.9, 1.5 mm MgCl2, 10 mm KCl, 1 mm DTT, 0.5 mm PMSF) using 
a Dounce homogenizer and centrifuged at 4 °C for 20 min at 11,000 × g. The supernatants, used as the cytosolic 
fraction in the Western blot assays, were stored at −80 °C. The pellets, containing the nuclear fraction, were resus-
pended in extraction buffer (20 mm HEPES, pH 7.9, 25% glycerol, 1.5 mm MgCl2, 300 mm NaCl, 0.25 mm EDTA, 
0.5 mm DTT, 0.5 mm PMSF), kept on ice for 30 min, and centrifuged at 4 °C for 5 min at 20,000 × g. All buffers 
were complemented with the Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, Inc.). 
The resulting supernatants containing nuclear proteins were stored at −80 °C. Protein concentration was deter-
mined using the Bradford method (BioRad Laboratories, Inc.)57. For the total extract, dorsal hipocamppi were 
sonicated in a cold homogenization buffer (Tris-HCl 20 mM - pH 7.5; EDTA 1 mM; DTT 1 mM; PMSF 1 mM; 
leupeptin 2 μg/μl; pepstatin 1 μM). The pellet was removed by low-speed centrifugation at 1,100 × g × 20 min at 
4 °C. The resulting supernatants containing nuclear proteins were stored at −80 °C. Protein concentration was 
determined using the Bradford method (BioRad Laboratories, Inc.)58.
Western blot assay. Electrophoresis was performed using a 10% polyacrylamide gel and the Mini-Protean® 
Tetra Cell apparatus (BioRad Laboratories, Inc.). The proteins present in the cytosolic and nuclear fractions were 
combined with an equal or a quarter part of the supernatant volume with Laemmli’s buffer (BioRad Laboratories, 
Inc.; complemented with 5% 2-mercaptoethanol) and boiled at 95 °C for 5 min. Protein samples (20 µg/lane) 
were size-separated in 10% SDS-PAGE gel (90 V) and then blotted onto Immobilon® PVDF membrane (EMD 
Millipore Corporation). Ponceau method to immunoblot was used to ensure equal protein loading59. Blots were 
blocked with 5% non-fat milk or bovine serum albumin (BSA), for phosphorylated proteins, diluted in TBS-T 
buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20, pH 7.5) for 1 hour at room temperature, and subse-
quently incubated overnight at 4 °C with specific antibodies: GR, EGR-1 (1:1000, Santa Cruz Biotechnology); 
Thr202/tyr204phospho-ERK1/2, ERK1/2 (1:5000 Cell Signaling Technology); CREB and Ser133phospho-CREB 
(1:1000, Cell Signaling Technology). After incubation with the primary antibodies, the membranes were then 
probed with a secondary antibody conjugated to horseradish peroxidase (dilution of 1:2000–1:4000, Kirkegaard 
& Perry Laboratories) for 2 hours at room temperature and developed by ECL-Immobilon® reagent (EMD 
Millipore Corporation). Chemiluminescent bands were quantitatively analyzed by optical density analysis using 
ChemiDoc MP Imaging System Detection System and Image Lab software (BioRad). Several exposure times 
were analyzed to ensure the linearity of the band intensities. The relative density of each band was normalized to 
the value of α-Tubulin, GAPDH or β-actin (dilution of 1:10000, Santa Cruz Biotechnology). The ratio between 
phospho-ERK-1/2 and total ERK-1/2 and CREB and phospho-CREB expression was used as phosphorylation 
index, and the ratio between the nuclear and cytosolic expression of GR was computed as the nuclear transloca-
tion index, and therefore, transcriptional activity.
Hippocampal DnGR Viral injection. Amplicon construction of DnGR. DnGR was generated as previ-
ously described (Kaufer et al., 2004) and was kindly donated by Dr. Ki Ann Goosens (McGovern Institute for 
Brain Research, MIT, Cambridge, MA-USA). A bicistronic herpes simplex viral vector (p1005-HSV) was used 
to pack the HSV-GFP and DnGR vectors. Amplicons were generated using 5dl1.2 helper virus as described in60.
Mouse HSV Infusions and EAE induction. Mice were anesthetized with a ketamine/xylazine mixture (keta-
mine 100 mg/kg and xylazine 10 mg/kg) and prepared for stereotaxic surgery. Thirty-three-gauge syringe needles 
(Hamilton) were used to infuse 0.5 µl of virus bilaterally into the CA1 hippocampal region (1.8 mm anteropos-
terior and 1.5 mm lateral, from Bregma, and 1,2 mm dorsoventral from dura) at a rate of 0.1 µl/2 min. Animals 
could recover between 3 and 6 days (peak of viral expression) after HSV delivery and then were induced with EAE 
and treated with DEX as described earlier. Viral injection sites were confirmed by searching for the GFP signal in 
the brain slices using a fluorescence microscope.
Experimental design and statistical analysis. Different behavioral tests were performed between 8 dpi 
as outlined in Fig. 1A. For clinical scores analysis, the data were treated as repeated measures, and the differences 
between the experimental and the control groups were detected by unpaired T-test. Two-way ANOVA was used 
when more than 2 experimental groups were analyzed followed by post-hoc Bonferroni test. In these situations, 
disease conditions (Control or EAE) and treatment (saline or DEX) were between-subject factors. The level of sig-
nificance was set at a maximum of 5% (p < 0.05) for all tests. Data are presented as the mean ± standard error of 
the mean (SEM). The F values and experimental degrees of freedom (DF) are included in the Results session. All 
analyzes were performed using the GraphPad Prism7 software package, GraphPad Software, San Diego, CA, USA.
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